Transforming growth factor beta (TGF-β) superfamily ligands (TGF-β superfamily ligands)

Transforming growth factor beta (TGF-β) superfamily ligands, specifically Growth Differentiation Factor 11 (GDF11) and GDF8 (myostatin), play a critical role in regulating erythropoiesis by acting as negative regulators of red blood cell maturation (Suragani et al., Nature Medicine, 2014). In conditions like beta-thalassemia and myelodysplastic syndromes, overproduction or overactivity of these ligands leads to ineffective erythropoiesis and chronic anemia (Fenaux et al., NEJM, 2020). Luspatercept is a first-in-class erythroid maturation agent designed as a recombinant fusion protein that functions as a ligand trap. It consists of the extracellular domain of the human activin receptor type IIB (ActRIIB) linked to a human IgG1 Fc domain. By binding and sequestering these specific TGF-β superfamily ligands, luspatercept prevents them from signaling through endogenous receptors, thereby diminishing SMAD2/3 phosphorylation and allowing for the progression of late-stage erythrocyte precursors into mature red blood cells (Cappellini et al., NEJM, 2020).

Other names

TGF-beta ligandsGDF11GDF8MyostatinActivin receptor ligandsGrowth differentiation factors

Luspatercept acts as a soluble decoy receptor (ligand trap) that binds to specific TGF-β superfamily ligands, such as GDF11 and GDF8, preventing them from activating the activin receptor type IIB (ActRIIB). By sequestering these inhibitory ligands, the drug reduces SMAD2/3 signaling, which normally suppresses late-stage erythropoiesis, thereby promoting the maturation of red blood cells (FDA Label, 2019; Suragani et al., Nature Medicine, 2014).